Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR plus /estrogen receptor (ER) plus breast cancer in an international phase 2 clinical study.

被引：30

作者：

Palmieri, Carlo

Linden, Hannah M.

Birrell, Stephen

Lim, Elgene

Schwartzberg, Lee S.

Rugo, Hope S.

Cobb, Patrick Wayne

Jain, Kirti

Vogel, Charles L.

O'Shaughnessy, Joyce

Johnston, Stephen R. D.

Getzenberg, Robert H.

Barnette, K. Gary

Steiner, Mitchell S.

Brufsky, Adam

Overmoyer, Beth

机构：

[1] Clatterbridge Canc Ctr NHS Fdn Trust, Wirral, Merseyside, England

[2] Univ Washington, Seattle Canc Care Alliance, Med Ctr, Seattle, WA USA

[3] Wellend Hlth Burnside Hosp, Toorak Gardens, Australia

[4] Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia

[5] West Canc Ctr, Memphis, TN USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Frontier Canc Ctr, Billings, MT USA

[8] Ashland Bellefonte Canc Ctr, Ashland, KY USA

[9] Sylvester Deerfield Beach, Deerfield, FL USA

[10] US Oncol, Baylor Sammons Canc Ctr, Texas Oncol, Dallas, TX USA

[11] Royal Marsden NHS Fdn Trust, London, England

[12] Veru Inc, Miami, FL USA

[13] GTx Inc, Memphis, TN USA

[14] UPMC, NSABP NRG Oncol, Pittsburgh, PA USA

[15] UPMC, Hillman Canc Ctr, Pittsburgh, PA USA

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.1020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1020

引用

页数：4